# Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 0p-1-2

> **NCT03283007** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 58 (actual)

## Conditions studied

- Lung-transplant Recipients

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03283007
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-30
- **Primary completion:** 2025-03-30
- **Final completion:** 2025-03-30
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03283007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03283007, "Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 0p-1-2". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03283007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*